Table 1 Baseline and summary characteristics of included studies
Characteristics of All included Studies | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Author, year | Type of Study | Country | Patients (n) (DCB/stent) | Type of patients | BMI (kg/m2) (DCB/stent) | Age (mean) (DCB/stent) | male, n (DCB/stent) | mean follow up (days) | Outcomes reported | Premedication | Lesion preparation | DCB type | Stent type | in-stent restenosis, % | de lovo lesions, n | small vessel lesions, n | large vessel lesions, n |
Scheller 2020 [21] | RCT | Germany | 104\106 | NSTEMI | 28.7\28.4 | 66\67 | 69\72 | 276 | MACE/stent thrombosis//TLR/MI/CD | aspirin plus clopidogrel, ticagrelor or prasugrel | Balloon dilation | paclitaxel iopromide-coated DCB | Paclitaxel | exclusion criteria | Inclusion citeria but no data | exclusion criteria | |
Vos 2019 [29] | RCT | The Netherlands | 60\60 | STEMI | 26.7\27.4 | 57.4\57.3 | 52\52 | 270 | MACE/CD/ MI/TLR | aspirin plus ticagrelor or prasugrel | Thrombus aspiration and/ or balloon dilation | Paclitaxel | Sirolimus or Everolimus(Orsiro, Biotronik; or Xience, Abbott, Abbott Park, Illinois) | exclusion criteria | 60/60 | NA | NA |
Wang 2022 [16] | RCT | China | 92\92 | STEMI | N.A | 49.2\49.6 | 88\84 | 365 | MACE/CD/ MI/TLR/MLD/LLL | Aspirin/Clopidogrel/ β-blocker/Calcium channel blocker/RAS inhibitor/ Statin/Ezetimib/Nitrate | Thrombus aspiration and/ or balloon dilation | Paclitaxel | sirolimus | exclusion criteria | Inclusion citeria but no data | NA | |
Yang 2023 [10] | Observtional | China | 67\209 | STEMI | 27.9\27.7 | 38.7\39.4 | 66\196 | 365 | MACE/CD/ MI/TLR | Aspirin/Clopidogrel/Ticagrelor/β-blocker/Calcium channel blocker/RAS inhibitor/ Statin/Ezetimib/Nitrate | Thrombus aspiration and/ or balloon dilation | N.A | N.A | exclusion criteria | NA | NA | NA |
Belkacemi 2012 [27] | RCT | the Netherlands/Italy | 50\49\51 | STEMI | N.A | 59.7\59.9 | 41\41\42 | 180 | MACE/ LLL | acetylsalicylic acid/clopidogrel/Heparin/glycoprotein IIb/IIIa inhibitors | Thrombus aspiration and/ or balloon dilation | DIORVR coronary angio- plasty balloon | paclitaxel DES | 10\9 | 50/49 | NA | NA |
Besic 2015 [15] | RCT | Croatia | 41\44 | NSTEMI | 29\28.1 | 63\68 | 33\35 | 180 | MACE/LLL/TLR/ST | clopidogrel/aspirin/unfractionated heparin/glycoproglycoprotein (GP) IIb/IIIa inhibitors (eptifibatide) | Thrombus aspiration and/ or balloon dilation | Elutax and SeQuent Please (B. Braun AG, Melsungen, Germany) | new cobalt chromium stent (Genius Magic stent, Eurocor) | exclusion criteria | 41/44 | NA | NA |
García-Touchard 2017 [24] | RCT | Spain | 110\112 | STEMI | 27.7\27.5 | 60\62 | 94\96 | 365 | MACE/CD/TLR/MLD/LLL | aspirin/clopidogrel/prasugrel/ticagrelor/Heparin/glycoprotein IIb/IIIa inhibitors | Thrombus aspiration and/ or balloon dilation | paclitaxel-eluting balloon | new cobalt chromium stent (Genius Magic stent, Eurocor) | exclusion criteria | NA | NA | NA |
Gobić 2017 | RCT | Croatia | 38\37 | STEMI | 29.4\28.2 | 57\45 | 71\73 | 180 | CD/MI/TLR/ST/LLL | acetylsalicylic acid/clopidogrel/unfractionated heparin | thrombus aspiration or balloon dilation | Sequent Please (B.Braun,Melsungen, Germany) | Sirolimus (Biomime, Meril Life Sciences, Vapi, India) | NA | Inclusion citeria but no data | exclusion criteria | |
Hao 2021 | RCT | China | 38\42 | STEMI | 26\25 | 59\56 | 30\35 | 365 | MACE/ LLL/TLR | enteric-coated aspirin tablets/ clopidogrel/ atorvastatin calcium/ anti-hypertensive and blood sugar control treatments for underlying diseases | thrombus aspiration and balloon expansion | N.A | N.A | exclusion criteria | NA | NA | NA |
Merinopoulos 2023 [28] | Observtional | UK | 452/687 | STEMI | NA | 66/66 | 330/509 | 365 | MACE/mortality/stent thrombosis/TLR | acetylsalicylic acid/clopidogrel/Heparin/glycoprotein IIb/IIIa inhibitors | Thrombus aspiration and/ or balloon dilation | paclitaxel-eluting balloon | Sirolimus (Biomime, Meril Life Sciences, Vapi, India) | exclusion criteria | 452/687 | NA | Inclusion citeria but no data |
Wang 2020 [19] | RCT | China | 38/42 | STEMI | 26/25 | 59/56 | 79/83 | 365 | CD, MI, TLR, LLL | aspirin plus clopidogrel | Thrombus aspiration and/ or balloon dilation | Sequent Please | DES | NA | NA | NA | NA |
Liu 2020 [18] | RCT | China | 33/32 | STEMI | NA | NA | NA | 365 | CD, MI, TLR, ST, 12 LLL | aspirin plus ticagrelor | Balloon dilation | Sequent Please | Xience V DES | exclusion criteria | Inclusion citeria but no data | NA | |
Characteristics of All included Studies | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Author, year | upfront hybrid PCI (DCB + DES), % | Bailout stenting rate in the DCB (%) | DAPT (months) (DCB/ stent) | Medical Conditions, n (DCB/ stent) | Angiographic assessment, (DCB/ stent) | |||||||||||
History of stroke | History of MI | DM | HTN | Hyperlipidaemia | Current smoker | PAD | LAD, n | LCx, n | RCA, n | Number of stents implanted, mean | Stent diameter, mean | stent length, mean | ||||
Nijhoff 2015 [15] | NA | 10% | N.A | N.A | 2\3 | 5\2 | 14/15 | 7\16 | 21\28 | N.A | 18/18 | NA | 13/20 | NA | NA | NA |
Scheller 2020 [21] | 15% | 15% | 12\12 | 6\9 | 20\17 | 28/38 | 82\93 | 52\48 | 35\43 | 9\7 | 51/46 | 40/44 | 32/30 | NA | 2.6/2.5 | 18.6/17.4 |
Vos 2019 [29] | NA | 18% | 12\12 | N.A | N.A | 8\4 | 18\19 | 10\8 | 28\24 | 1\0 | 19/24 | NA | 29/28 | NA | NA | NA |
Wang 2022 [16] | NA | 9.50% | 3\12 | N.A | 92\92 | 71\79 | 67\65 | 61\58 | N.A | N.A | 64/64 | 24/19 | 29/30 | 1.27/1.23 | 2.69/2.7 | 16.92/16.97 |
Yang 2023 [10 | exclusion criteria | NA | 6\12 | 3\8 | 67\209 | 15\36 | 31\95 | 18\44 | 53\173 | N.A | 19/96 | 29/35 | 19/78 | 1\2 | 2.57/3 | 26/30 |
Belkacemi 2012 [27] | NA | NA | 12\12 | N.A | 1\2\0 | 3\2\6 | 17\15\18 | 13\16\11 | 19\28\29 | N.A | 24/18 | 13\11 | 13/20 | 1.3/1.2 | 2.98/2.88 | 24.4/25.4 |
Besic 2015 [15] | NA | NA | 12\12 | N.A | 4\6 | 13\12 | 41\44 | 36\39 | 18\9 | N.A | 22/16 | 2\6 | 14/15 | 1\1 | 3\3 | 18/18 |
García-Touchard 2017 [24] | NA | NA | 12\12 | N.A | 3\5 | 15\22 | 42\55 | 45\57 | 81\81 | N.A | 25/36 | 23/20 | 62/56 | NA | 3\3 | 18.8/18 |
Gobić 2017 | NA | 7.30% | 12\12 | N.A | N.A | 5\11 | 32\35 | 9.5\18.9 | 43.9\56.8 | N.A | NA | NA | NA | NA | NA | NA |
Hao 2021 | NA | 4%% | 6\12 | N.A | N.A | 10\15 | 8\12 | N.A | 24\28 | N.A | 19/22 | 7\8 | 12\12 | NA | NA | NA |
Merinopoulos 2023 [28] | NA | 5.30% | 12\12 | 18\12 | 30/35 | 63/83 | 183/241 | 79/100 | 254/435 | 7\7 | 196/256 | 78/103 | 175/321 | NA | NA | NA |
Wang 2020 [19] | NA | 9.50% | 6\12 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Liu 2020 [18] | NA | 5.70% | 12\12 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |